Synergistic interaction between prostaglandins and PAF-acether in experimental animals and man.
Platelet activating factor (PAF-acether) is released from a variety of inflammatory cell types and has properties appropriate to a mediator of allergy and inflammation. Here, we have examined the interaction between PAF-acether and the prostaglandins, PGE2 and ZK 36374 (a stable analogue of prostacyclin, PGI2) in the skin of guinea-pigs and human volunteers. PGE2 and ZK 36374 significantly potentiated increased plasma protein extravasation induced by PAF-acether in guinea-pigs, assessed by extravasation of I-125-HSA. In addition, PGE2 significantly potentiated the ability of PAF-acether to elicit acute wheal (volume) and flare responses in human skin. The inflammatory properties of PAF-acether should not be considered in isolation since this phospholipid interacts synergistically with prostaglandins which are recognised as modulators of inflammation.
D000818:Animals; D002317:Cardiovascular Agents; D015232:Dinoprostone; D004357:Drug Synergism; D011464:Epoprostenol / Q000494:pharmacology; D006168:Guinea Pigs; D006801:Humans; D016285:Iloprost; D010972:Platelet Activating Factor / Q000494:pharmacology; D011458:Prostaglandins E / Q000494:pharmacology; D012709:Serum Albumin / Q000378:metabolism*; D012867:Skin / Q000187:drug effects / Q000276:immunology*
D002317:Cardiovascular Agents; D010972:Platelet Activating Factor; D011458:Prostaglandins E; D012709:Serum Albumin; D011464:Epoprostenol; D016285:Iloprost; D015232:Dinoprostone